Human Neurocan Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: Neurocan

Neurocan, also known as CSPG3 and 1D1, is a secreted chondroitin sulfate proteoglycan that is primarily expressed in the central nervous system (1). Human Neurocan contains one Ig-like V-type domain, two Link domains, two EGF-like domains, one C‑type lectin-like domain, and one Sushi domain (2). It is an approximately 300 kDa molecule of which 66 kDa is chondroitin sulfate and 60 kDa is N‑ and O‑linked glycosylation (3). Mature human Neurocan shares 66% aa sequence identity with mature mouse and rat Neurocan. Human Neurocan is predicted to be cleaved following Met635, resulting in N-terminal (Neurocan-130) and C‑terminal (Neurocan-C) fragments whose core glycoproteins are 130 kDa and 150 kDa, respectively (4, 5). The full length molecule is expressed in the developing and juvenile brain, while its cleavage products are found throughout adulthood (3, 4). Neurocan and Neurocan-C are produced by astrocytes and accumulate in the matrix surrounding axonal bundles and neuronal cell bodies; Neurocan-130 is found mainly in the glial cell cytoplasm (6-8). Following brain injury, reactive astrocytes deposit increased amounts of Neurocan in the glial scar where it impedes axonal regeneration (6, 9). Neurocan inhibits neuronal adhesion and neurite outgrowth through interactions with a variety of matrix and transmembrane molecules including NCAM-L1, NCAM-1, Syndecan-3, Glypican-1, Tenascin, Contactin-2/TAG1, and HAPLN1 (1, 6, 10-15).

Product Datasheets

Related Research Areas

• Hyaluronan (HA) and HA-binding Proteins
• Proteoglycans